B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NTLA
Intellia TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The positive HAELO Phase 3 result, anticipated BLA acceptance in H2 2026, potential H1 2027 launch, resumed ATTR enrollment and runway into 2028 create a credible path from clinical-stage valuation toward commercial biotech valuation [#SEC-8K-2026-08-06].
Posture
Constructive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-09-09.
What can break
ATTR Phase 3 restart, enrollment and safety execution may disappoint despite resumed activity.
Momentum
31
Value
41
Sentiment
92
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $15.00 · Bull $24.00 · Bear $7.50Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $23.81
Why
Momentum31 · Δ7d +2.2
Value41 · Δ7d -0.0
Sentiment92 · Δ7d +6.1
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +6.1.
Contradictions & invalidation
- • ATTR Phase 3 restart, enrollment and safety execution may disappoint despite resumed activity.
- • Commercial infrastructure, reimbursement, pricing and patient uptake remain unproven.
- • The thesis remains concentrated in lonvo-z regulatory and commercial execution.
Catalyst clock
2026-11-06
FDA BLA acceptance watch for lonvo-z
Lead driver: Sentiment · See AI snapshot
Momentum
31
9% active weight
Current posture
7d trendFlat
Δ7d
+2.2
Δ21d
+14.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
92
62% active weight
Current posture
7d trendImproving
Δ7d
+6.1
Δ21d
-7.2
Why this grade
Composite grade A. Momentum 31.1 / Value 41.2 / Sentiment 92.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.69B
Beta
2.09
Shares Out
140.13M
P/E (TTM) · Derived
-3.2
P/S (TTM)
18.87
P/FCF (TTM) · Derived
-4.13
Rev YoY
-46.2%
EPS YoY
-18.2%
Gross Margin
+74.4%
Op Margin
-711.7%
Net Debt
-$356.56M
Current Ratio
6.65
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data